Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

A at week 20 of post-treatment follow-up. Of the remaining 8 patients enrolled in Arm D, 4 discontinued due to adverse events prior to week 12, and 4 did not achieve RVR.

Interim 12-Week Safety Analysis of PROVE 1

In PROVE 1, the types of adverse events that have been commonly observed with interferon and ribavirin were seen across all treatment arms. The most common adverse events, regardless of treatment assignment, were fatigue, rash, headache and nausea. Gastrointestinal disorders, rash and anemia were more common in the telaprevir arms.

In the telaprevir dosing arms, the incidence of treatment discontinuations due to adverse events through 12 weeks was 11% (19 of 175 patients), compared to 3% (2 of 75 patients) in the control arm. The difference between the two groups is due to the greater number of discontinuations due to rash, gastrointestinal disorders and anemia in the telaprevir arms compared to the control arm. The most common reason for treatment discontinuation in the telaprevir arms was rash (7 patients), and the median time to discontinuation in these patients was 64 days.

Webcast of Investor Presentation

Vertex intends to provide a live webcast of its investor presentation from Barcelona beginning at 7:30 p.m. CEST (1:30 p.m. EDT) on Saturday, April 14. The presentation may be accessed from the 'Events Calendar' on the homepage of Vertex's website at www.vrtx.com. A replay of the webcast will also be available on the Company's website until April 27, 2007. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.

About Telaprevir (VX-950)

Telaprevir (VX-950) is an investigational oral inhibitor of HCV protease, an enzyme essential for viral replication, and is one of the most advanced investigational agents in development that specifically targets HCV. Vertex is conducting a global Phase 2b clinical development program for telaprevir consis
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... VG Energy, a subsidiary of Viral Genetics, Inc. ... that it has retained alternative energy producer BioProcess ... for the development of commercial production of its potential ... with results reproduced multiple times from test-tube to small-pond ...
... 2011 Watson Pharmaceuticals, Inc. (NYSE: WPI ... for the District of Delaware has ruled that Watson,s ... United States Patent No. 6,264,981 (the ,981 Patent).  The ... and would evaluate all available options, including an appeal. ...
Cached Medicine Technology:VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 2VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 3VG Energy Contracts BioProcess Algae To Verify "Lipid Trigger" Results For Commercial Biofuels Production 4Watson Confirms District Court Ruling in Generic Fentora® Patent Suit 2
(Date:4/23/2014)... SEATTLE, Washington, April 21, 2014 Five for-profit ... total of $1.25 million in Proof of Concept ... from ideas into commercial products, the Life Sciences ... a $300,000 Entrepreneur Mentoring Program grant to the ... a statewide advisory network to train the next ...
(Date:4/23/2014)... journal Oncotarget , explored tumour heterogeneity ... own DNA signatures within the same cancer. Such ... targeted treatment strategies. , Firstly they confirmed the ... the KRAS or BRAF mutation. Secondly, they found ... mutation have that specific mutation present uniformly throughout ...
(Date:4/22/2014)... popular high school sport in the United States with ... researchers in the Center for Injury Research and Policy ... and describe the occurrence and distribution patterns of basketball-related ... athletic training setting among adolescents and teens. , The ... Training , examined data relating to adolescents 13-19 years ...
(Date:4/22/2014)... can provide primary care for low-income patients may ... insurance companies while improving patient health, researchers have ... that health clinics that avoid costs associated with ... lowering hospital admission rates and emergency room visits, ... State Altoona. , The researchers estimated that ...
(Date:4/22/2014)... Association for Molecular Pathology (AMP) released a report ... on recommendations for a molecular diagnostics curriculum ... education. The report was prepared by the Medical ... AMP Training and Education Committee. "Our goal was ... medical laboratory scientists appropriately in order to manage ...
Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... ... longest continuously running plastic surgery practice in the nation is launching an ... Long Island Plastic Surgical Group, PC, a practice offering reconstructive and ... interactive media to provide web visitors with a thorough virtual tour of ...
... Speaker Nancy Pelosi released the following statement on a ... the Center for American Progress that shows that health insurance ... than would be created without reform. The report finds that health care reform ... to 400,000 per year over the coming decade. , "We know ...
... ... Health and Development Groups Applaud Clinton Speech; Call for Action ... of Americans applauded today,s statement by Secretary of State Hillary Clinton that ... to reproductive health is critical for individual health, family well-being, broader economic ...
... , , SILVER SPRING, ... has agreed to stop producing and distributing its medical products ... is in compliance with FDA quality standards. The products are ... FDA clearance review and approval for safety and effectiveness. The ...
... , CLEVELAND, Jan. 8 RSB Spine, ... ended Dec. 31, 2009, versus year-end 2008, and a 42% ... 2009. Additionally, the company reported that it achieved an important ... , RSB Spine Chief Executive Officer John A. Redmond said: ...
... a resurgence could occur, CDC experts warn, , FRIDAY, Jan. ... outbreak eases to a point where it is now widespread ... Americans to get their swine flu shot. , "On Sunday ... the U.S. Department of Health and Human Services, said during ...
Cached Medicine News:Health News:Long Island Plastic Surgical Practice - the Largest in the U.S. - Opens Virtual Doors on a New, State-of-the-Art Website 2Health News:Long Island Plastic Surgical Practice - the Largest in the U.S. - Opens Virtual Doors on a New, State-of-the-Art Website 3Health News:Long Island Plastic Surgical Practice - the Largest in the U.S. - Opens Virtual Doors on a New, State-of-the-Art Website 4Health News:U.S. Government Rejoins Worldwide Consensus on Reproductive Health 2Health News:U.S. Government Rejoins Worldwide Consensus on Reproductive Health 3Health News:U.S. Government Rejoins Worldwide Consensus on Reproductive Health 4Health News:U.S. Government Rejoins Worldwide Consensus on Reproductive Health 5Health News:U.S. Government Rejoins Worldwide Consensus on Reproductive Health 6Health News:U.S. Government Rejoins Worldwide Consensus on Reproductive Health 7Health News:FDA Requires Sybaritic, Inc. to Stop Producing Unapproved Medical Devices 2Health News:FDA Requires Sybaritic, Inc. to Stop Producing Unapproved Medical Devices 3Health News:As Swine Flu Ebbs, Officials Stress Importance of Vaccine 2Health News:As Swine Flu Ebbs, Officials Stress Importance of Vaccine 3
... Massive hemorrhage associated with displaced pelvic fractures ... faced by orthopaedic and trauma surgeons. , ... antishock garment, external fixation, and internal fixation ... Stabilizer has been developed as a method ...
The large External Fixator consists of rods, clamps, and pins. It has multiple external fixation frames, independent pin placement, and MR safe clamps. The modular frame construction permits fracture...
The DFS Standard Fixator advantages include a highly adjustable system, modular compression/distraction, versatile central body component that provides 360 of rotation, and a positive locking mechani...
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: